Clinical Trial Update: A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II study of oral HP568 tablets in patients with ER-positive/HER2 advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HP568

Snippet

Sponsor: Hinova Pharmaceuticals Inc. | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING